drugset / Trial / NCT03480672
Postoperative aRCH With Cisplatin Versus aRCH With Cisplatin and Pembrolizumab in Locally Advanced Head and Neck Squamous Cell Carcinoma
RandomizedParallel-groupOpen-labelTreatment
Summary
This trial evaluates the addition of pembrolizumab to standard postoperative adjuvant radiochemotherapy in the treatment of patients with locally advanced intermediate and high risk head and neck squamous cell carcinoma (HNSCC).
Timeline
- Start
- 2018-08-06
- Primary completion
- 2025-01-30
- Completion
- 2025-01-30
Publications
- Background Wiegand S, Wichmann G, Vogt J, Vogel K, Franke A, Kuhnt T, Lordick F, Scheuble AM, Hambsch P, Brossart P, Bauernfeind FG, Kaftan H, Maschmeyer G, Paland M, Munter M, Lewitzki V, Rotter N, Stromberger C, Beck M, Dommerich S, Gauler TC, Hapke G, Guntinas-Lichius O, Schroder U, Gorner M, Hautmann MG, Steger F, Tamaskovics B, Schmiedeknecht A, Dietz A. Postoperative adjuvant radiochemotherapy with cisplatin versus adjuvant radiochemotherapy with cisplatin and pembrolizumab in locally advanced head and neck squamous cell carcinoma- the study protocol of the Adrisk trial. Front Oncol. 2023 Mar 21;13:1128176. doi: 10.3389/fonc.2023.1128176. eCollection 2023.
- Results A. Dietz, S. Wiegand, J. Vogt, K. Vogel, A. Schmiedeknecht, A. Schrock, T. Kuhnt, P. Hambsch, N. Nicolay, F. Lordick, A.M. Scheuble, P. Brossart, F.-G. Bauernfeind, G. Feldmann, S. Parade, H. Kaftan, S. Wohlfarth, M. Jungehülsing, M. Paland, G. Maschmeyer, G. Hapke, P. Ebeling, N. Rotter, A. Affolter, M. Muenter, F. Zangos, D. Hahn, V. Lewitzki, U. Müller-Richter, S. Hackenberg, C. Stromberger, M. Heiland, S. Dommerich, M. Beck, T.C. Gauler, S. Lang, B.F. Tamaskovics, W. Budach, U. Schroeder, D. Rades, M. Görner, M. Hautmann, F. Steger, O. Guntinas-Lichius, K. Pietschmann, M. Pirlich, T. Wald, A. Franke, G. Wichmann 1320O Postoperative adjuvant radiochemotherapy with cisplatin (aRCH) vs. aRCH plus pembrolizumab in locally advanced head and neck squamous cell carcinoma (HNSCC): First data of the ADRISK trial Annals of Oncology Volume 36, Supplement 2, September 2025, Page S769
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pembrolizumab | Monoclonal antibody | 200 mg | Intravenous |